All In MedTech

FDA Clearance Tracker · P170024-S003

Surpass Evolve Flow Diverter System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 20, 2020 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 20, 2020

Approved

Time to decision

443 days

Received Mar 4, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P170024-S003
Device name
Surpass Evolve Flow Diverter System
Applicant location
Fremont, CA
Received
Mar 4, 2019
Decided
May 20, 2020
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P170024

Device type

Device class
Class III

Every decision under product code OUT

FDA's approval statement

As written in FDA's record.

Approval for a change in the design of the approved Surpass Streamline Flow Diverter that consists of a new delivery system, smaller gauge wire in the stent to enable delivery through a smaller microcatheter, and reduce the number of cobalt chromium wires used in the stent braid.

Source documents

Other decisions for Stryker Neurovascular

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.